Skip to content

Anticoagulant Treatments and Percutaneous Coronary Angioplasty

Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00669149
Acronym
TACA
Enrollment
99
Registered
2008-04-29
Start date
2008-06-30
Completion date
2013-08-03
Last updated
2019-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

ptca, antiaggregant therapy, anticoagulant therapy

Brief summary

The purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in selected patients.

Detailed description

* Background : We don't know if using IV anticoagulant therapy is necessary for percutaneous coronary angioplasty in stable patients. * Purpose : to compare efficacy and security of use or not of different anticoagulant treatments during percutaneous coronary angioplasty in patients with double antiaggregant therapy. * Abstract : In stable patients pretreated with double antiaggregant therapy use of IV anticoagulants has not been yet evaluated during angioplasty. In this prospective randomized trial we want to compare in such patients the efficacy and security of the administration of IV heparin, IV enoxaparin, IV bivalirudin and no use of anticoagulant during coronary angioplasty. We will evaluate in each group ischaemic events (clinic, ECG and biology) and haemorrhagic events (clinic, biology) with a one month follow up. * Primary outcome: ischaemic events via troponin Ic measurements during 24 hours post procedure. * Secondary outcomes: haemorrhagic events : clinical and biological evaluation (Hb, Ht, TIMI score) * Study design : monocentric randomized clinical trial type therapeutic equivalence phase IV. * Interventions : In patients prepared with therapeutic association (aspirin clopidogrel) comparison between use or no of anticoagulant (IV heparin, IV enoxaparin or IV bivalirudin). * Number of subjects : 120 per group (total of 480). * Statistical analysis : multivariate analysis with logistic regression models : each end point (troponin Ic increase, haemoglobin decrease, …) will be explicated with treatment group and other covariates (sex, age, creatinine, …).

Interventions

DRUGheparin + clopidogrel + aspirin
DRUGenoxaparin + clopidogrel + aspirin
DRUGbivalirudin + clopidogrel + aspirin

Sponsors

Centre Hospitalier de PAU
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* stable angina pectoris or silent ischaemia

Exclusion criteria

* instable angina or ACS (Acute Coronary Syndrome)

Design outcomes

Primary

MeasureTime frame
ischaemic events via troponin Ic measurements during 24 hours post procedure24 hours

Secondary

MeasureTime frame
haemorrhagic events : clinical and biological evaluation24 hours

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026